Renalytix AI—developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. incorporated in March 2018 as a subsidiary of EKF Diagnostics Holdings (AIM-EKF). Total fundraising in the range £21 - 25 m. Mkt cap - c. £67.5- £71.0m. Due 2 Nov.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA
Kropz PLC—an emerging plant nut ....
25 Oct 2018
Small Cap Feast
Alumasc Group plc (ALU:LON), 172 | Centaur Media plc (CAU:LON), 39.5 | Aura Energy Limited (AURA:LON), 8.8 | Smart Metering Systems PLC (SMS:LON), 952 | Begbies Traynor Group plc (BEG:LON), 108 | Reabold Resources plc (RBD:LON), 0.1 | Feedback plc (FDBK:LON), 130 | Oriole Resources PLC (ORR:LON), 0.3 | Mattioli Woods plc (MTW:LON), 794 | BiON Plc (8YZ:STU), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
Alumasc Group plc (ALU:LON), 172 | Centaur Media plc (CAU:LON), 39.5 | Aura Energy Limited (AURA:LON), 8.8 | Smart Metering Systems PLC (SMS:LON), 952 | Begbies Traynor Group plc (BEG:LON), 108 | Reabold Resources plc (RBD:LON), 0.1 | Feedback plc (FDBK:LON), 130 | Oriole Resources PLC (ORR:LON), 0.3 | Mattioli Woods plc (MTW:LON), 794 | BiON Plc (8YZ:STU), 0
- Published:
25 Oct 2018 -
Author:
Derren Nathan - Pages:
Renalytix AI—developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. incorporated in March 2018 as a subsidiary of EKF Diagnostics Holdings (AIM-EKF). Total fundraising in the range £21 - 25 m. Mkt cap - c. £67.5- £71.0m. Due 2 Nov.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA
Kropz PLC—an emerging plant nut ....